Insider Selling: uniQure (NASDAQ:QURE) Director Sells 2,645 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 2,645 shares of uniQure stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $30.01, for a total transaction of $79,376.45. Following the completion of the sale, the director directly owned 20,439 shares in the company, valued at $613,374.39. This trade represents a 11.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

Shares of NASDAQ:QURE traded down $1.54 during mid-day trading on Friday, reaching $26.45. The company had a trading volume of 1,448,107 shares, compared to its average volume of 2,673,993. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -7.60 and a beta of 0.98. The company’s 50-day moving average price is $21.19 and its 200-day moving average price is $21.83. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The company had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. As a group, equities research analysts anticipate that uniQure N.V. will post -3.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of QURE. Torren Management LLC purchased a new position in uniQure in the 4th quarter valued at approximately $28,000. Jones Financial Companies Lllp grew its stake in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares in the last quarter. IFP Advisors Inc purchased a new position in uniQure in the 4th quarter valued at approximately $48,000. Smartleaf Asset Management LLC purchased a new position in uniQure in the 4th quarter valued at approximately $48,000. Finally, CIBC Private Wealth Group LLC purchased a new position in uniQure in the 3rd quarter valued at approximately $50,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on QURE shares. HC Wainwright lowered their price target on shares of uniQure from $70.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Barclays lowered their price target on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, March 23rd. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $12.00 to $35.00 in a report on Wednesday, March 11th. The Goldman Sachs Group lifted their price objective on shares of uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a research note on Monday, April 20th. Finally, Sanford C. Bernstein lowered shares of uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.83.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.